索拉非尼联合顺铂对人肝癌裸鼠移植瘤生长的抑制作用  

Sorafenib combined with cisplatin inhibit the growth of hepatocellular carcinom a tumor xenografts in mice

作　　者：陈逢生[1] 崔彦芝[1] 郑航[1] 罗荣城[1] 

机构地区：[1]南方医科大学附属南方医院,广州510515

出　　处：《山东医药》2009年第48期9-11,共3页Shandong Medical Journal

基　　金：广东省科技计划项目(2008B030301144)

摘　　要：目的探讨多靶点酪氨酸激酶抑制剂索拉非尼联合顺铂(DDP)对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法构建人肝癌细胞HepG2裸鼠皮下移植瘤模型,随机分为空白对照组、溶剂对照组、索拉非尼组、DDP组和联合用药组。观察用药前后肿瘤大小,测体质量,并计算瘤重,绘制肿瘤生长曲线;应用免疫组化检测肿瘤微血管密度(MVD)。结果索拉非尼和DDP单药均能抑制肿瘤生长,两药联合疗效明显增强(P<0.05)。与对照组和顺铂组相比,索拉非尼组和联合用药组能明显抑制肿瘤血管生成,MVD值均明显降低,以联合用药组最为明显(P均<0.05)。结论索拉非尼联合DDP能增强抑制人肝癌裸鼠移植瘤的生长及微血管生成。Objective To investigate inhibitory effect of sorafenib combined with cisplatin （DDP） against HepG2 hepatocellular carcinoma （HCC） tumor xenografts. Methods Established HepG2 HCC xenograft models. Mice were divided into 5 groups： untreated control group, vehicle control group, sorafenib-treated group, DDP-treated group and combination treatment group. Tumor dimensions and body weights were recorded twice weekly starting with the first day of treatment. Microvessel density （MVD） was examined by immunohistochemistry. Results Sorafenib and DDP alone were efficacious against HepG2 HCC tumor xenografts. The efficacy of combination was significantly better than sorafenib or DDP adminis- tered alone （P 〈 0.05 ）. The immunohistochemistry results showed that the MVD were reduced in sorafenib group, espe- cially in combination groups （P 〈 0.05 ）. Conclusion Sorafenib combined with DDP can greatly inhibit the growth and angiogenesis of tumor in HCC xenograft models.

关 键 词：肝肿瘤 索拉非尼 顺铂 裸鼠 

分 类 号：R730.5[医药卫生—肿瘤]